Verification of the Efficacy of Mexiletine Treatment for the A1656D Mutation on Downgrading Reentrant Tachycardia Using a 3D Cardiac Electrophysiological Model

The SCN5A mutations have been long associated with long QT variant 3 (LQT3). Recent experimental and computation studies have reported that mexiletine effectively treats LQT3 patients associated with the A1656D mutation. However, they have primarily focused on cellular level evaluations and have onl...

Descripción completa

Detalles Bibliográficos
Autores principales: Qauli, Ali Ikhsanul, Yoo, Yedam, Marcellinus, Aroli, Lim, Ki Moo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9598628/
https://www.ncbi.nlm.nih.gov/pubmed/36290499
http://dx.doi.org/10.3390/bioengineering9100531

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9598628/
https://www.ncbi.nlm.nih.gov/pubmed/36290499
http://dx.doi.org/10.3390/bioengineering9100531

Ejemplares similares